The rationale for adding lenalidomide to the R-CHOP backbone for MYC-R DLBCL is the MYC-downregulating effect of lenalidomide via cereblon targeting [16, 17]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.